Back to results
US 11,111,271 B2Granted
Therapeutic peptides
AssigneeCohbar, Inc.
InventorsKenneth C. Cundy, Kent K. Grindstaff, Remi Magnan, Wendy Luo, Yongjin Yao, Liang Zeng Yan
Life of this patent
Estimating the term…
Abstract
Provided herein are peptides and peptide analogs and methods of treating a metabolic disease, e.g., obesity, diabetes, methods of treating cancer, methods of treating a liver disease, and methods of modulating fatty acid metabolism.
Claims33
A peptide comprising the amino acid sequence of formula I:
- (I)
- (SEQ ID NO:
- 1)
- X1-QE-X2-X3-YI-X4-Y-X5-R-X6
- wherein
- X1 is absent or if present is X7—RW, wherein X7 is absent or if present is M or E;
- X2 is M, A or E;
- X3 is G, N or Q;
- X4 is F or A;
- X5 is P or A;
- X6 is absent or if present is KL-X8 or X9-LR, wherein X8 is absent or if present is R or A and X9 is selected from K, A, (dA), N and Q;
- wherein the amino acid sequence of formula I is selected from the group consisting of:
- (SEQ ID NO:
- 11)
- MRWQEAGYIFYPRKLR;
- (SEQ ID NO:
- 149)
- MRWQEMGYIFYPR(dA)LR;
- (SEQ ID NO:
- 208)
- MRWQEMNYIFYPR;
- (SEQ ID NO:
- 213)
- MRWQEMGYIFYPRNLR;
- (SEQ ID NO:
- 219)
- MRWQEMQYIFYPRALR;
- (SEQ ID NO:
- 248)
- RWQEMNYIFYPR;
- (SEQ ID NO:
- 19)
- MRWQEMGYIFYPRALR;
- (SEQ ID NO:
- 21)
- MRWQEMGYIFYPRKLA;
- (SEQ ID NO:
- 17)
- MRWQEMGYIFYARKLR;
- (SEQ ID NO:
- 217)
- RWQEMGYIFYPRQLR;
- (SEQ ID NO:
- 172)
- MRWQEEGYIFYPRKLR;
- (SEQ ID NO:
- 241)
- ERWQEAGYIAYPR;
- and
- (SEQ ID NO:
- 211)
- RWQEMQYIFYPR;
- or C-terminal acids or amides, or N-acetyl derivatives thereof;
- or
- pharmaceutically acceptable salts thereof.
52 more elements
A peptide comprising the amino acid sequence of formula I:
- X1-QE-X2—X3—YI—X4—Y—X5—R—X6 (I) (SEQ ID NO:
- 1)
- wherein
- X1 is absent or if present is X7—RW, wherein X7 is absent or if present is M or E;
- X2 is M, A or E;
- X3 is N or Q;
- X4 is F or A;
- X5 is P or A;
- and
- X6 is absent or if present is KL-X8 or X9-LR, wherein X8 is absent or if present is R or A and X9 is selected from K, A, (dA), N and Q;
- or pharmaceutically acceptable salts thereof,
- or C-terminal acids or amides, or N-acetyl derivatives thereof;
- or pharmaceutically acceptable salts thereof.
10 more elements
A peptide or peptide analog comprising both RWQE (SEQ ID NO:
- 294) and YIFY (SEQ ID NO:
- 295), wherein the peptide or peptide analog is 8 to 20 amino acids in length, and wherein the peptide or peptide analog:
- (i) exhibits at least a 20% stability in mouse plasma for 60 minutes at 37 degrees Celsius,
- (ii) decreases free fatty acid levels in human primary adipocytes, or
- (iii) or both (i) and (ii).
2 more elements
Dependencies are inferred from the claim text.